Characteristics and treatment of hospitalized patients with CHF

The article analyzes some characteristics of hospitalized patients with decompensated chronic heart failure (HF) according to data from Russian and international registries, management of decompensated HF, and tactics for titration of evidence-based disease-modified therapies. The demographic characteristics of the patients from the registers that were used for the research are similar. Yet, the proportion of HF patients with preserved LVEF was greater according to data from several Russian studies. Meanwhile, with the patients that did not receive any loop diuretics and therefore had apparently no congestion signs being excluded from the analysis, the proportion of HF patients with preserved LVEF became similar to that from the international studies. The registers also showed that pulmonary edema and acute left ventricular failure were observed in less than a half of the cases. Nevertheless, patients with mild congestion symptoms still have bad lingering prognosis and require the same amount of medical attention. Up to 40% of admissions for decompensated CHF resulted from a dietary disorder (excessive sodium consumption), low compliance with therapy and lack of access to primary care providers. Furthermore, the analysis of the outpatient treatment administered prior to the forthcoming hospitalization showed a low prescription rate of evidence-based disease-modifying therapies (ACEi or ARNi, BB, MRA). It is emphasized that in part of patients the administration and/or titration of this therapy can be started during hospitalization. The article also discusses the use of a new class of drugs, angiotensin receptor-neprilysin inhibitors (ARNi), including not only transferring patients from ACEi to ARNi but also the possibility of administering ARNi to stable, hospitalized patients who do not require intravenous diuretics and inotropic drugs.

ХСН, госпитализации по поводу сердечной недостаточности, декомпенсация сердечной недостаточности, ангиотензиновых рецепторов и неприлизина ингибиторы (АРНИ), CHF, heart failure hospitalizations, decompensated heart failure, angiotensin receptor-neprilysin inhibitor (ARNI)

1. Belenkov Yu. N., Mareev V. Yu., Ageev F. T. Khronicheskaya serdechnaya nedostatochnost': izbrannye lektsii po kardiologii. Moskva: GEOTAR-Media; 2006. 432 s.

2. Belenkov Yu. N., Mareev V. Yu. Lechenie serdechnoi nedostatochnosti v XXI veke: dostizheniya, voprosy i uroki dokazatel'noi meditsiny. Kardiologiya. 2008;48 (2):6-16.

3. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al. Angiotensin - niprilysin Inhibition versus enalaβ pril in heart failure. New England Journal of Medicine. 2014;371 ( 11 ) :993-1004. https://doi.org/10.1056/NEJMoa1409077.

4. Heidenreich PA, Sahay A, Kapoor JR, Pham MX, Massie B. Divergent Trends in Survival and Readmission Following a Hospitalization for Heart Failure in the Veterans Affairs Health Care System 2002 to 2006. Journal of the American College of Cardiology. 2010;56 (5):362-8. https://doi.org/10.1016/j. jacc. 2010.02.053.

5. Torre-Amione G, Milo-Cotter O, Kaluski E, Perchenet L, Kobrin I, Frey A et al. Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome. J Card Fail. 2009;15 (8):639-44. https://doi.org/10.1016/j. cardfail. 2009.04.001.

6. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363 (15):1419-28. https://doi.org/10.1056/NEJMoa0912613.

7. Metra M, Teerlink JR, Felker GM, Greenberg BH, Filippatos G, Ponikowski P et al. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. Eur J Heart Fail. 2010;12 (10):1130-9. https://doi.org/10.1093/eurjhf/hfq132.

8. Packer M, O'Connor C, McMurray JJV, Wittes J, Abraham WT, Anker SD et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017;376 (20):1956-64. https://doi.org/10.1056/NEJMoa1601895.

9. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. The Lancet. 2013;381 (9860):29-39. https://doi.org/10.1016/S0140-6736 (12) 61855-8.

10. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal. 2007;154 (2):260-6. https://doi.org/10.1016/ j. ahj. 2007.01.041.

11. Jain P, Massie BM, Gattis WA, Klein L, Gheorghiade M. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. Am Heart J. 2003; 145 (2 Suppl): S3-17. https://doi.org/10.1067/mhj. 2003.149.

12. Sitnikova M. Yu., Lelyavina T. A., Shlyakhto E. V., Vologdina I. V. Osobennosti kliniki, diagnostikii prognoza khronicheskoi serdechnoi nedostatochnosti u gospitalizirovannykh patsientov starcheskogo vozrasta. Zhurnal Serdechnaya Nedostatochnost'. 2006;7 (2 (36)): 85-7.

13. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42 (7):1226-33.

14. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59 (11):998-1005. https://doi.org/10.1016/j. jacc. 2011.11.040.

15. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet. 2010;376 (9744):875-85. https://doi.org/10.1016/S0140-6736 (10) 61198-1.

16. Packer M, Fowler MB, Roecker EB, Coats AJS, Katus HA, Krum H et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106 (17):2194-9.

17. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH et al. Rosuvastatin in older patients with systolic heart failure. New England Journal of Medicine. 2007;357 (22):2248-61. https://doi.org/10.1056/NEJMoa0706201.

18. Torp-Pedersen C, Poole-Wilson PA, Swedberg K, Cleland JGF, Di Lenarda A, Hanrath P et al. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure - COMET. Am Heart J. 2005; 149 (2):370-6. https://doi.org/10.1016/j. ahj. 2004.10.002.

19. Polyakov D. S., Fomin I. V., Valikulova F. Yu., Vaisberg A. R., Kraiem N., Badin Yu. V. i dr. Epidemiologicheskaya programma EPOKhA-KhSN: dekompensatsiya khronicheskoi serdechnoi nedostatochnosti v real'noi klinicheskoi praktike (EPOKhA-D-KhSN). Zhurnal Serdechnaya Nedostatochnost'. 2016;17 (6):299-305. https://doi.org/10.18087/rhfj. 2016.5.2239.

20. Sato N, Kajimoto K, Asai K, Mizuno M, Minami Y, Nagashima M et al. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J. 2010; 159 (6):949-955. e1. https://doi.org/10.1016/j. ahj. 2010.03.019

21. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15 https://doi.org/808-17.DOI:10.1093/eurjhf/hft050

22. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52 (5):347-56. https://doi.org/10.1016/j. jacc. 2008.04.028

23. Mareev V. Yu., Fomin I. V., Ageev F. T., Arutyunov G. P., Begrambekova Yu. L., Vasyuk Yu. A. i dr. Khronicheskaya serdechnaya nedostatochnost' (KhSN). Zhurnal Serdechnaya Nedostatochnost'. 2017;18 (1):3-40. https://doi.org/10.18087/rhfj. 2017.1.2346.

24. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC: Heart Failure. 2013;1 (2):103-11. https://doi.org/10.1016/j. jchf. 2012.12.004.

25. Cuffe MS, Califf RM, Adams KF, Benza R, Bourge R, Colucci WS et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287 (12):1541-7.

26. Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, Boas FV et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Medicine. 2011;37 https://doi.org/290-301.DOI:10.1007/s00134-010-2073-4

27. Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46 (1):57-64. https://doi.org/10.1016/j. jacc. 2005.03.051

28. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: The ROSE acute heart failure randomized trial. JAMA. 2013;310 (23):2533. https://doi.org/10.1001/jama. 2013.282190.

29. Cotter G, Metra M, Davison BA, Jondeau G, Cleland JGF, Bourge RC et al. Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe? Eur J Heart Fail. 2017; https://doi.org/10.1002/ejhf. 889.

30. Matsue Y, Damman K, Voors AA, Kagiyama N, Yamaguchi T, Kuroda S et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69 (25):3042-51. https://doi.org/10.1016/j. jacc. 2017.04.042.

31. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR et al. Diuretic strategies in patients with acute decompensated heart failure. New England Journal of Medicine. 2011;364 (9):797-805. https://doi.org/10.1056/NEJMoa1005419.

32. ter Maaten JM, Dunning AM, Valente MAE, Damman K, Ezekowitz JA, Califf RM et al. Diuretic response in acute heart failure-an analysis from ASCEND-HF. Am Heart J. 2015;170 (2):313-21. https://doi.org/10.1016/j. ahj. 2015.05.003

33. Mareev V. Yu., Vygodin V. A., Belenkov Yu. N. DiUrueticheskaya terapiya Effektivnymi dozami peroraL''nykh diuretikov torasemida (Diuver®) i furosemida v lechenii bol'nykh s obostreniem Khronicheskoi Serdechnoi Nedostatochnosti (DUEL''-KhSN). Zhurnal Serdechnaya Nedostatochnost'. 2011;12 (1):3-10

34. Mentz RJ, Cotter G, Cleland JGF, Stevens SR, Chiswell K, Davison BA et al. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. Eur J Heart Fail. 2014;16 (6):614-24. https://doi.org/10.1002/ejhf. 92.

35. Eapen ZJ, Reed SD, Li Y, Kociol RD, Armstrong PW, Starling RC et al. Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF. Circ Heart Fail. 2013;6 (4):727-32. https://doi.org/10.1161/CIRCHEARTFAILURE. 112.000265.

36. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. 2013;34 (11):835-43. https://doi.org/10.1093/eurheartj/ehs444.

37. Mareev V. Yu., Arutyunov G. P., Astashkin E. I., Vertkin A. L., Glezer M. G., Lopatin Yu. M. i dr. Ostraya dekompensirovannaya serdechnaya nedostatochnost'. Soglasovannaya pozitsiya rossiiskikh ekspertov - 2014. Zhurnal Serdechnaya Nedostatochnost'. 2014;15 (5):321-36. https://doi.org/10.18087/rhfj. 2014.5.2024.

38. Mareev Yu. V., Gerasimova V. V., Goryunova T. V., Petrukhina A. A., Danielyan M. O., Kapanadze L. G. i dr. Faktory, opredelyayushchie prognoz pri khronicheskoi serdechnoi nedostatochnosti: rol' shiriny i morfologii kompleksa QRS. Zhurnal Serdechnaya Nedostatochnost'. 2012;13 (5):255-66.

39. Shoaib A, Waleed M, Khan S, Raza A, Zuhair M, Kassianides X et al. Breathlessness at rest is not the dominant presentation of patients admitted with heart failure. Eur J Heart Fail. 2014;16 (12):1283-91. https://doi.org/10.1002/ejhf. 153.

40. Shavarova E. K., Padar'yan S. S., Lukina O. I., Mil'to A. S., Babaeva L. A., Soseliya N. N. Khronicheskaya serdechnaya nedostatochnost': rekomendatsii i real'naya klinicheskaya praktika. Ratsional'naya farmakoterapiya v kardiologii. 2016;12 (6):631-7.

41. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37 (27):2129-200. https://doi.org/10.1093/eurheartj/ehw128.

42. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110 (17):2618-26. https://doi.org/10.1161/01. CIR. 0000146819.43235. A9.

43. Gilotra NA, Shpigel A, Okwuosa IS, Tamrat R, Flowers D, Russell SD. Patients commonly believe their heart failure hospitalizations are preventable and identify worsening heart failure, nonadherence, and a knowledge gap as reasons for admission. J Card Fail. 2017;23 (3):252-6. https://doi.org/10.1016/j. cardfail. 2016.09.024.

44. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. New England Journal of Medicine. 1987;316 (23):1429-35. https://doi.org/10.1056/NEJM198706043162301.

45. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37 (5):455-62. https://doi.org/10.1093/eurheartj/ehv464.

46. Kotecha D. Efficacy of beta-blockers in heart failure according to left ventricular ejection fraction: An individual patient level analysis of double-blind randomised trials [Internet]. [cited 2017]. Available from: http://congress365.escardio.org/Presentation/162249#.WjYgFFVl_ csURL http://congress365.escardio.org/Presentation/162249*. WjYgFFVl_cs (accessed 12.17.17).

47. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325 (5):293-302. https://doi.org/10.1056/NEJM1991080132 50501.

48. Correction to: 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management ofHeart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134 (13):e298. https://doi.org/10.1161 /CIR. 0000000000000460.

49. Packer M, McMurray JJV, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al. Angiotensin receptor niprilysin Inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131 (1):54-61. https://doi.org/10.1161/CIRCULATIONAHA. 114.013748.

50. Böhm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017;38 (15):1132-43. https://doi.org/10.1093 / eurheartj / ehw570.

51. Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K et al. Efficacy of sacubitril/valsartan relative to a prior decompensation: The PARADIGM-HF Trial. JACC Heart Fail. 2016;4 (10):816-22. https://doi.org/10.1016/j. jchf. 2016.05.002.

52. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344 (22):1651-8. https://doi.org/10.1056/NEJM2001 05313442201.

53. Poole-Wilson PA, Swedberg K, Cleland JGF, Di Lenarda A, Hanrath P, Komajda M et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362 (9377):7-13. https://doi.org/10.1016/S0140-6736 (03) 13800-7.

54. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al. Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine. 2011;364 (1): 11-21. https://doi.org/10.1056/NEJMoa1009492.

55. Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J. 2005;26 (16):1653-9. https://doi.org/10.1093/eurheartj/ehi251.

56. Heidenreich PA, Hernandez AF, Yancy CW, Liang L, Peterson ED, Fonarow GC. Get With The Guidelines program participation, process of care, and outcome for Medicare patients hospitalized with heart failure. Circ Cardiovasc Qual Outcomes. 2012;5 (1):37-43. https://doi.org/10.1161/CIRCOUTCOMES. 110.959122.

57. Moon J, Ko Y-G, Chung N, Ha J-W, Kang S-M, Choi E-Y et al. Recovery and recurrence of left ventricular systolic dysfunction in patients with idiopathic dilated cardiomyopathy. Can J Cardiol. 2009;25 (5):e147-150.

58. Belenkov Yu. N., Ageev F. T., Banshchikov G. T., Volkova E. G., Gilyarevskii S. R., Donova I. G. i dr. Vliyanie spetsializirovannykh form aktivnogo ambulatornogo vedeniya na funktsional'nyi status, kachestvo zhizni i pokazateli gemodinamiki bol'nykh s vyrazhennoi serdechnoi nedostatochnost'yu. Rezul'taty Rossiiskoi programmy «ShANS». Zhurnal Serdechnaya Nedostatochnost'. 2007;8 (3):112-6.

59. Mareev V. Yu., Begrambekova Yu. L., Danielyan M. O., Ageev F. T., Gilyarevskii S. R., Belenkov Yu. N. i dr. Kakie voprosy zadayutsya i na kakie voprosy sposobny otvetit' issledovaniya po nemedikamentoznomu lecheniyu patsientov s serdechnoi nedostatochnost'yu. Uroki issledovaniya ShANS. Zhurnal Serdechnaya Nedostatochnost'. 2014;15 (6):383-96.

60. Ageev F. T., Mareev V. Yu., Seredenina E. M., Belenkov Yu. N. Perspektivy vnedreniya spetsializirovannykh form aktivnogo ambulatornogo vedeniya bol'nykh s serdechnoi nedostatochnost'yu: struktura, metodika i predvaritel'nye rezul'taty Rossiiskoi programmy «ShANS». Zhurnal Serdechnaya Nedostatochnost'. 2004;5 (6):268-71.